CGT

CGTLimited DatastalePrecision BioSciences, Inc.Phase 2

PBCAR20A (PBCAR20A)

Non-Hodgkin's Lymphoma, Relapsed; Chronic Lymphoid Leukemia in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5

CGTLimited DatastalePrecision BioSciences, Inc.Phase 1

PBCAR269A (PBCAR269A)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4

CGTLimited DatastaleGreat Ormond Street Hospital fo…Phase 1

PBLTT52CAR19 (PBLTT52CAR19)

B Acute Lymphoblastic Leukemia · B Acute Lymphoblastic Leukemia

#BAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+2

CGTLimited DatastaleShanghai Cell Therapy Research …Phase 2

PD-1 antibody expressing mesoCAR-T cells (PD-1 antibody expressing mesoCAR-T cells)

Advanced Solid Tumor · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3

CGTLimited DatastaleNingbo Cancer HospitalPhase 2

PD-1 antibody expressing mesothelin specific CAR-T cells (PD-1 antibody expressing mesothelin specific CAR-T cells)

Solid Tumor, Adult; Advanced Cancer · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+5

CGTLimited DatastaleDaihong LiuPhase 2

PD-1Ab21-BCMA CAR-T cell immunotherapy (PD-1Ab21-BCMA CAR-T cell immunotherapy)

Multiple Myeloma · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3

CGTLimited DatastaleBioray LaboratoriesPhase 1

PD1-PSMA-CART cells (PD1-PSMA-CART cells)

Castrate-Resistant Prostate Cancer · PSMA

#PSMA#CGT#Phase1#cell-gene-therapy#CAR-T+3

CGTLimited DatastaleStephan Grupp MD PhDPhase 1

PHOX2B PC-CAR T Cells (PHOX2B PC-CAR T Cells)

Refractory Neuroblastoma; Relapsed Neuroblastoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4

CGTLimited DatastalePrecigen, IncPhase 1

PRGN-3005 UltraCAR-T cells (PRGN-3005 UltraCAR-T cells)

Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4

CGTLimited DatastaleShanghai Changzheng HospitalPhase 1

BRL-302 (PSMA-UCAR T, PSMA-UCAR T (BRL-302))

Metastatic Prostate Cancer; Castration-resistant Prostate Cancer · PSMA

#PSMA#CGT#Phase1#cell-gene-therapy#CAR-T+4

CGTLimited DatastalePinze Lifetechnology Co. Ltd.Phase 1

PZ01 CAR-T cells (PZ01 CAR-T cells)

B-cell Acute Lymphoblastic Leukemia; B-cell Lymphoma · B-cell Acute Lymphoblastic Leukemia

#B-cellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3

CGTLimited DatastaleChinese PLA General HospitalPhase 2

Pan-T booster co-expressing MSLN CAR T cell (Pan-T booster co-expressing MSLN CAR T cell)

Advanced or Metastatic Solid Tumors · Advanced or Metastatic Solid Tumors

#AdvancedorMetastaticSolidTumors#CGT#Phase2#cell-gene-therapy#CAR-T+2

CGTLimited DatastaleThe Evan FoundationPhase 1

2nd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells))

Neuroblastoma; Ganglioneuroblastoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4

CGTLimited DatastaleSeattle Children's HospitalPhase 1

3rd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells))

Neuroblastoma; Ganglioneuroblastoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4

CGTLimited DatastaleThe Evan FoundationPhase 1

long spacer 2nd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells))

Neuroblastoma; Ganglioneuroblastoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4

CGTLimited DatastaleOttawa Heart Institute Research…Phase 3

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)

Stable Coronary Artery Disease; Acute Coronary Syndrome · Stable Coronary Artery Disease

#StableCoronaryArteryDisease#CGT#Phase3#cell-gene-therapy#CAR-T+3

CGTLimited DatastaleNovartis PharmaceuticalsPhase 3

Previously treated CAR-T patients (Previously treated CAR-T patients)

Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program · Long Term Safety of Patients Receiving C

#LongTermSafetyofPatientsReceivin#CGT#Phase3#cell-gene-therapy#CAR-T+2

CGTLimited DatastaleMustang BioPreclinical

Prior MB-102 CAR-T cell investigational product. (Prior MB-102 CAR-T cell investigational product.)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Chronic Lymphocytic Leukemia in Relapse · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4

CGTLimited DatastaleMustang BioPreclinical

Prior MB-106 CAR-T cell investigational product. (Prior MB-106 CAR-T cell investigational product.)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Chronic Lymphocytic Leukemia in Relapse · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4